Plain-English translation of NCT06749691 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether liposomal irinotecan combined with apatinib can help treat advanced small cell lung cancer that has stopped responding to initial chemotherapy and immunotherapy. Liposomal irinotecan is a chemotherapy drug packaged in a special coating to help it reach cancer cells more effectively, while apatinib is a targeted drug that stops blood vessels from feeding tumors. The researchers believe using these two medications together may work better than current second-line treatment options.
After most people with advanced small cell lung cancer receive first-line treatment, their cancer often comes back and becomes harder to treat. Current second-line treatment options don't work very well and cancer cells can develop resistance, so doctors need better options to help patients live longer and feel better.
You likely qualify if…
You likely don't qualify if…
You would receive the medication combination as a participant in this study, with your doctor closely monitoring how well the treatment works and how your body tolerates it. The trial will track your tumor response through imaging scans and blood tests at regular visits. You'll need to be involved long enough for the researchers to see whether this treatment combination is effective and safe for people in your situation.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Enrollment target
~30 participants
Started
December 2024
Primary completion
December 2027
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in December 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Xian Zhong
Second Affiliated Hospital, School of Medicine, Zhejiang University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.